Although tyrosine kinase inhibitors (TKIs) against BCR-ABL represent the standard therapeutic option for CML, resistances to TKIs can be a serious problem. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.